Trial intelligence / Profile preview

Neratinib plus capecitabine in solid tumors and HER2-positive metastatic or locally advanced breast cancer

CTR20182194Phase 2Completed

Sponsor

Puma Biotechnology, Inc.

Start

Feb 2019

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1